Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TERT | O14746 | 2/20 | 0.53 |
| ▸ | DTYMK | P23919 | 2/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276800 | 0.96 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29567368 | 0.96 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29551577 | 0.96 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29371610 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29365434 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29424735 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL29702417 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL4078522 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL15127423 | 0.94 | TERT (0.62) | P2RY2P2RY4P2RY6POLBTERT | |
| SCHEMBL22930707 | 0.94 | POLB (0.64) | P2RY2P2RY4P2RY6POLBTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2025-12-04 | — | — | US | disclosed |
| CN-111936471-B | Non-fused thiophene derivatives and uses thereof | 埃尼奥制药公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117757965-A | Primer probe combination, kit and application for constant-temperature rapid detection of vibrio corallolyticus | 中国科学院南海海洋研究所 | 2024-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | PTPRCAP, PTPRC, CD47 | P2RY2 3235/4885P2RY4 3687/4885P2RY6 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.